[Bronchodilator effects of an atropinic compound: oxitropium pressurized aerosol. Comparison with theophylline in asthma].
Oxitropium bromide (Tersigat pressurized aerosol) is a new anticholinergic agent. Two puffs of 100 micrograms given in 27 adult patients with asthma produced a 33% mean increase in FEVI, significantly bigger than the 20.9% increase obtained by an intra-muscular injection of theophylline (240 mg) in the same patients.
D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D006801:Humans; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D013806:Theophylline / Q000627:therapeutic use*
D000336:Aerosols; D001993:Bronchodilator Agents; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C017590:oxitropium; D013806:Theophylline
Effets bronchodilatateurs d'un atropinique: l'oxitropium aérosol-doseur. Comparaison avec la théophylline dans l'asthme.